Exact Sciences Corporation EXAS NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

36/100

1/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Exact Sciences Corporation (EXAS) generated $491.44M in operating cash flow for fiscal year 2025. After capital expenditures of $134.66M, free cash flow was $356.78M.

Free cash flow margin was 11% of revenue. Cash conversion ratio was -2.36x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (71/100, Pass) — $356.78M (11% FCF margin) supports a durable competitive advantage
INCOME (10/100) — Cash conversion ratio was -2.36x suggests some earnings are non-cash items

Overall SharesGrow Score: 36/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

36/100

SG Score

View full scorecard →

✗

VALUE

35/100

Price-to-Earnings & upside

→ Valuation

✗

FUTURE

38/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

✓

MOAT

71/100

Proven by this page

GROWTH

48/100

→ Income

✗

INCOME

10/100

→ Income

Exact Sciences Corporation Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$491.44M	$491.44M	$210.54M	$156.12M	$-223.56M
Capital Expenditure	$-134.66M	$-134.66M	$-135.99M	$-124.19M	$-214.46M
Free Cash Flow	$356.78M	$356.78M	$74.55M	$31.93M	$-438.02M